The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 03, 2024

Filed:

Aug. 14, 2019
Applicant:

Sotio Biotech Inc., Boston, MA (US);

Inventors:

Kathleen McGinness, Cambridge, MA (US);

Seth Ettenberg, Cambridge, MA (US);

Luke Barron, Cambridge, MA (US);

Michael Fray, Cambridge, MA (US);

Charles Wilson, Cambridge, MA (US);

Gregory Motz, Cambridge, MA (US);

Assignee:

SOTIO BIOTECH INC., Boston, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 9/04 (2006.01); A61K 35/17 (2015.01); A61K 48/00 (2006.01); A61P 35/00 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/30 (2006.01); C12N 9/06 (2006.01); C12N 9/10 (2006.01); C12N 9/80 (2006.01); C12N 9/88 (2006.01);
U.S. Cl.
CPC ...
C12N 9/0006 (2013.01); A61K 35/17 (2013.01); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C07K 16/303 (2013.01); C12N 9/0016 (2013.01); C12N 9/1096 (2013.01); C12N 9/80 (2013.01); C12N 9/88 (2013.01); C12Y 101/01037 (2013.01); C12Y 101/01042 (2013.01); C12Y 104/01002 (2013.01); C12Y 206/01001 (2013.01); C12Y 206/01002 (2013.01); C12Y 206/01052 (2013.01); C12Y 305/01002 (2013.01); C12Y 401/01032 (2013.01); A61K 48/00 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01);
Abstract

Disclosed herein are genetically engineered hematopoietic cells, which express one or more Krebs cycle modulating polypeptides, and optionally a chimeric receptor polypeptide (e.g., an antibody-coupled T cell receptor (ACTR) polypeptide or a chimeric antigen receptor (CAR) polypeptide) capable of binding to a target antigen of interest. Also disclosed herein are uses of the engineered hematopoietic cells for inhibiting cells expressing a target antigen in a subject in need thereof.


Find Patent Forward Citations

Loading…